Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
A regenerative therapy for Alzheimer’s pathology using non-invasive gene delivery
EF 2020-21
Résumé
Alzheimer's Disease (AD) affects more than 30 million people worldwide and there is no effective treatment capable of modifying disease progression. With age being the main risk factor for the development of AD, increasingly aged populations across the globe poses a major threat to economies, healthcare infrastructures, and the well-being of patients and caretakers. A recent Canadian estimate suggests that the cost of the disease totals more than $10.4 billion annually, and national disease prevalence is expected to double by 2030. Given the urgent need for therapeutic advancement, the proposed project aims to develop an effective and long-lasting treatment for AD. Specifically, this project aims to develop a gene therapy that activates a receptor which prevents degeneration by promoting cell survival and function. A novel and non-invasive method that uses harmless ultrasound waves to access the brain will be used to ensure safe therapeutic delivery. Promoting brain health using ultrasound-mediated therapeutic delivery has shown promising results in animal models of AD; however, to date, this treatment requires frequent ultrasound applications for repeated therapeutic delivery which poses safety, feasibility, and efficacy concerns. The proposed approach eliminates this issue through its ability to deliver a gene which, after a single administration, allows for the production of a therapeutic compound for 10 or more years. Specifically, this therapy modifies brain cells and enables them to produce the therapy they need for their own survival, regeneration, and function. I hypothesize that this approach will slow disease progression in AD. This will be tested experimentally in an animal model of AD to bring us one step closer to clinical therapies.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
449488
Name
Renaud Matthew
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
A regenerative therapy for Alzheimer’s pathology using non-invasive gene delivery
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alzheimer'S Disease; Focused Ultrasound; Gene Therapy; Neurotrophins; Regenerative Medicine
Abstract
Alzheimer's Disease (AD) affects more than 30 million people worldwide and there is no effective treatment capable of modifying disease progression. With age being the main risk factor for the development of AD, increasingly aged populations across the globe poses a major threat to economies, healthcare infrastructures, and the well-being of patients and caretakers. A recent Canadian estimate suggests that the cost of the disease totals more than $10.4 billion annually, and national disease prevalence is expected to double by 2030. Given the urgent need for therapeutic advancement, the proposed project aims to develop an effective and long-lasting treatment for AD. Specifically, this project aims to develop a gene therapy that activates a receptor which prevents degeneration by promoting cell survival and function. A novel and non-invasive method that uses harmless ultrasound waves to access the brain will be used to ensure safe therapeutic delivery. Promoting brain health using ultrasound-mediated therapeutic delivery has shown promising results in animal models of AD; however, to date, this treatment requires frequent ultrasound applications for repeated therapeutic delivery which poses safety, feasibility, and efficacy concerns. The proposed approach eliminates this issue through its ability to deliver a gene which, after a single administration, allows for the production of a therapeutic compound for 10 or more years. Specifically, this therapy modifies brain cells and enables them to produce the therapy they need for their own survival, regeneration, and function. I hypothesize that this approach will slow disease progression in AD. This will be tested experimentally in an animal model of AD to bring us one step closer to clinical therapies.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Renaud, Matthew
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~